These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Synthesis and biological activity of naphthyl-substituted (B-ring) benzophenone derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. Ma XD; Zhang X; Dai HF; Yang SQ; Yang LM; Gu SX; Zheng YT; He QQ; Chen FE Bioorg Med Chem; 2011 Aug; 19(15):4601-7. PubMed ID: 21719299 [TBL] [Abstract][Full Text] [Related]
7. Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors. Ren J; Chamberlain PP; Stamp A; Short SA; Weaver KL; Romines KR; Hazen R; Freeman A; Ferris RG; Andrews CW; Boone L; Chan JH; Stammers DK J Med Chem; 2008 Aug; 51(16):5000-8. PubMed ID: 18665583 [TBL] [Abstract][Full Text] [Related]
8. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2. Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347 [TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase. Gomez R; Jolly SJ; Williams T; Vacca JP; Torrent M; McGaughey G; Lai MT; Felock P; Munshi V; Distefano D; Flynn J; Miller M; Yan Y; Reid J; Sanchez R; Liang Y; Paton B; Wan BL; Anthony N J Med Chem; 2011 Nov; 54(22):7920-33. PubMed ID: 21985673 [TBL] [Abstract][Full Text] [Related]
10. Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors. Yang S; Pannecouque C; Daelemans D; Ma XD; Liu Y; Chen FE; De Clercq E Eur J Med Chem; 2013 Jul; 65():134-43. PubMed ID: 23707918 [TBL] [Abstract][Full Text] [Related]
11. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Andries K; Azijn H; Thielemans T; Ludovici D; Kukla M; Heeres J; Janssen P; De Corte B; Vingerhoets J; Pauwels R; de Béthune MP Antimicrob Agents Chemother; 2004 Dec; 48(12):4680-6. PubMed ID: 15561844 [TBL] [Abstract][Full Text] [Related]
12. Differential impact of the HIV-1 non-nucleoside reverse transcriptase inhibitor mutations K103N and M230L on viral replication and enzyme function. Xu HT; Oliveira M; Quan Y; Bar-Magen T; Wainberg MA J Antimicrob Chemother; 2010 Nov; 65(11):2291-9. PubMed ID: 20852269 [TBL] [Abstract][Full Text] [Related]
13. Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. Delaugerre C; Rohban R; Simon A; Mouroux M; Tricot C; Agher R; Huraux JM; Katlama C; Calvez V J Med Virol; 2001 Nov; 65(3):445-8. PubMed ID: 11596076 [TBL] [Abstract][Full Text] [Related]
14. Synthesis of novel diarylpyrimidine analogues and their antiviral activity against human immunodeficiency virus type 1. Guillemont J; Pasquier E; Palandjian P; Vernier D; Gaurrand S; Lewi PJ; Heeres J; de Jonge MR; Koymans LM; Daeyaert FF; Vinkers MH; Arnold E; Das K; Pauwels R; Andries K; de Béthune MP; Bettens E; Hertogs K; Wigerinck P; Timmerman P; Janssen PA J Med Chem; 2005 Mar; 48(6):2072-9. PubMed ID: 15771449 [TBL] [Abstract][Full Text] [Related]
15. A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors. Zhang Z; Xu W; Koh YH; Shim JH; Girardet JL; Yeh LT; Hamatake RK; Hong Z Antimicrob Agents Chemother; 2007 Feb; 51(2):429-37. PubMed ID: 17116677 [TBL] [Abstract][Full Text] [Related]
16. Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine. Alcaro S; Alteri C; Artese A; Ceccherini-Silberstein F; Costa G; Ortuso F; Bertoli A; Forbici F; Santoro MM; Parrotta L; Flandre P; Masquelier B; Descamps D; Calvez V; Marcelin AG; Perno CF; Sing T; Svicher V ChemMedChem; 2011 Dec; 6(12):2203-13. PubMed ID: 21953939 [TBL] [Abstract][Full Text] [Related]
17. F18, a novel small-molecule nonnucleoside reverse transcriptase inhibitor, inhibits HIV-1 replication using distinct binding motifs as demonstrated by resistance selection and docking analysis. Lu X; Liu L; Zhang X; Lau TC; Tsui SK; Kang Y; Zheng P; Zheng B; Liu G; Chen Z Antimicrob Agents Chemother; 2012 Jan; 56(1):341-51. PubMed ID: 22037848 [TBL] [Abstract][Full Text] [Related]
18. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological activity of novel nonnucleoside inhibitors of HIV-1 reverse transcriptase. 2-Aryl-substituted benzimidazoles. Roth T; Morningstar ML; Boyer PL; Hughes SH; Buckheit RW; Michejda CJ J Med Chem; 1997 Dec; 40(26):4199-207. PubMed ID: 9435891 [TBL] [Abstract][Full Text] [Related]
20. Antiviral activity of MK-4965, a novel nonnucleoside reverse transcriptase inhibitor. Lai MT; Munshi V; Touch S; Tynebor RM; Tucker TJ; McKenna PM; Williams TM; DiStefano DJ; Hazuda DJ; Miller MD Antimicrob Agents Chemother; 2009 Jun; 53(6):2424-31. PubMed ID: 19289522 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]